Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATH434 dose level 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ATH434 Arm 1 | EXPERIMENTAL | - |
| ATH434 Arm 2 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ATH434 dose level 1 | DRUG | ATH434 taken BID |
| ATH434 dose level 2 | DRUG | ATH434 taken BID |
| Placebo | DRUG | Placebo taken BID |
Inclusion Criteria: 1. Participant has clinical features of parkinsonism. 2. Participant has evidence of orthostatic hypotension and/or bladder dysfunction. 3. Participant has ataxia and/or pyramidal signs on neurological examination. 4. Participant is ambulatory. 5. Participant has biomarker evide...
ATH434 dose level 1 is an investigational small molecule being studied for the treatment of Multiple System Atrophy (MSA), a rare neurological disorder. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated for its potential to slow disease progression in patients with MSA.
The specific molecular target of ATH434 dose level 1 has not been disclosed in the available information. The drug is a small molecule being investigated for its effects in Multiple System Atrophy, but its precise mechanism of action is not publicly detailed at this time.
ATH434 dose level 1 is being developed by Alterity Therapeutics Limited, a biopharmaceutical company listed on the NASDAQ under the ticker symbol ATHE. The company is conducting clinical research on this investigational drug for the treatment of Multiple System Atrophy.
ATH434 dose level 1 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Orphan Drug and Fast Track designations by the FDA for the treatment of Multiple System Atrophy.
ATH434 dose level 1 was studied in a Phase 2 clinical trial with the identifier NCT05109190, titled 'Study of ATH434 in Participants with Multiple System Atrophy'. This randomized, double-blind, placebo-controlled trial enrolled 77 participants and has been completed. The trial was conducted in the United States, Australia, France, Italy, New Zealand, and the United Kingdom.
ATH434 dose level 1 is a specific dose level of the investigational drug ATH434. The drug is being developed by Alterity Therapeutics for Multiple System Atrophy. The Phase 2 trial NCT05109190 evaluated ATH434 at this dose level, and the drug has received Orphan Drug and Fast Track designations from the FDA.